Bio-Rad Laboratories, Inc. manufactures and distributes a comprehensive array of life science research and clinical diagnostic products across various regions, including the United States, Europe, Asia, Canada, and Latin America. Operating through its Life Science and Clinical Diagnostics segments, the Life Science segment is dedicated to the development, manufacturing, and marketing of reagents, apparatus, and laboratory instruments utilized in diverse research techniques, biopharmaceutical production processes, and food testing regimes. It strategically focuses on selected areas within the life sciences market, such as proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves a wide range of clients, including universities, medical schools, industrial research organizations, governmental agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. On the other hand, the Clinical Diagnostics segment specializes in designing, manufacturing, and supporting test systems, informatics systems, test kits, and specialized quality controls tailored for clinical laboratories within the diagnostics market. It offers reagents, instruments, and software that cater to specific niches in the in vitro diagnostics test market, selling these products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Additionally, the company provides products and systems aimed at separating complex chemical and biological materials, as well as identifying, analyzing, and purifying components. Bio-Rad Laboratories, Inc. utilizes a direct sales force supplemented by distributors, agents, brokers, and resellers to market its products. Established in 1952, the company is headquartered in Hercules, California. The net total of other income and expenses is $725,000,000.00 reflecting non-core financial activities, while the cost of revenue for the company is $1,239,600,000.00 showcasing its production and operational expenses. Furthermore, the weighted average number of diluted shares outstanding is 27,281,000.00 reflecting potential dilution effects, and the weighted average number of shares outstanding is 27,263,000.00 highlighting the company's shareholder base. The EBITDA ratio is 0.18 underscoring the company's operational efficiency. Currently, the stock is priced at $284.07 positioning it in the higher-end market. However, it has a low average trading volume of 217,228.00 indicating lower market activity. With a mid-range market capitalization of $7,322,494,164.00 the company is viewed as a steady performer. Bio-Rad is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth through its advanced research and diagnostic solutions.